直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

First CBM Claims Survive Review, First Contested Motions to Amend Granted-in-Part

January 22, 2015

Authored and Edited by Aaron L. Parker

December was a big month—and an interesting way to end 2014—at the PTAB. As our updated statistics show, claims have finally survived CBM review, and the Board has granted-in-part the first set of contested Motions to Amend. See Riverbed Tech., Inc. v. Silver Peak Sys., Inc., IPRs2013-00402, -00403, Paper 33 (Dec. 30, 2014).

PTAB-STATS--IPR_Substitute_Claim-1.16.15

First, in a set of five CBMs styled Groupon, Inc. v. Blue Calypso, LLC, the petitioner successfully challenged 52 claims, including one entire patent—but 24 claims in four patents survived review.

CBM Case Cancelled Survived
Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00033, Paper 51 (Dec. 17, 2014) 15 12
Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00034, Paper 45 (Dec. 17, 2014) 5 0
Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00035, Paper 45 (Dec. 17, 2014) 26 2
Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00044, Paper 47 (Dec. 17, 2014) 0 6
Groupon, Inc. v. Blue Calypso, LLC, CBM2013-00046, Paper 46 (Dec. 17, 2014) 6 4

In those cases, the Board found the petitioner failed to prove that a printed publication used for many of the grounds to reject the claims—a technical report by a Dr. Olga Ratsimor—was a printed publication; they found it was not publicly accessible before the critical date. See, e.g., CBM2013-00033, Paper 51. Reasoning by analogy, the Board compared the purportedly internal technical report with theses placed in university libraries, and found that the lack of indexing or proof of public availability, among other things, doomed the petitioner’s use of the Ratsimor paper. Thus, the ground failed and the claims survived.

Second, the PTAB granted two more Motions to Amend on December 30, 2014. These related IPRs—the second and third Motions to Amend granted—mark the first grant of contested substitute claims. See Riverbed Tech., Inc. v. Silver Peak Sys., Inc., IPR2013-00402, -00403 Paper 35 (Dec. 30, 2014).

The petitioner proposed six substitute claims in each IPR. The Board granted two substitute claims in each—i.e., four out of twelve proposed substitute claims. (In contrast, they cancelled all 27 originally issued claims in one patent and all 12 originally issued claims in the other.)

The panel considered substitute claims in two related IPRs on two patents, granting some but denying others. One of the allowed substitute claims contained 332 words, compared to the original’s 37 words, according to a Microsoft Word word-count. See IPR2013-00402, Paper 35, at 8.

Special thanks to Daniel Klodowski, Elliot Cook, Joseph Schaffner, Kai Rajan, and Cara Lasswell for their help with statistics, support, and the project.

 

Tags

claim amendments, Final Written Decision, motions to amend (MTA), substitute claims

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Contacts

Aaron L. Parker
Partner
Washington, DC
+1 202 408 4387
Email

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Lecture

Munich Licensing Summer Course 2026

June 18-19, 2026

Munich

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP